The pharmaceutical giant Teva’s French division, Teva France, announced that the preliminary investigation conducted by the Paris Prosecutor resulted in the conclusion that there were no signs of Zopiclone in Furosemide tablets manufactured by Teva.
Therefore, the prosecutor decided that there is no connection between the Teva plant in Sens, France, where the drug Furosemide 40 mg was packed and the apparent substitution of those tablets, as was reported by a pharmacist in the town of Saint-Malo.
Two elderly women, 89- and 100-years-old, died last month in France after reportedly taking Furosemide 40 mg that was manufactured by Teva.
The case involves Zopiclone which was mistakenly sold in packaging for Furosemide. Teva says that the error was discovered by a pharmacist, after a patient who took the medication suffered from unusual sleepiness. A test found that the incident involved two problematic packages, which the company recalled.
President and CEO of Teva, Dr. Jeremy Levin, stated that ” the results of the investigation clears Teva of all suspicion of operational failure. For Teva, the well being and safety of patients are top priority, and we are committed to adhering to the highest standards in manufacturing and complying with all relevant regulations.”